RxDoctor Payments Data

Jeffrey Garrett, OD

Optometrist · Lake Oswego, ORNPI 1144204025

Payments from drug & device makers

$802in general payments, 2019–2025

Across 19 payments — averaging $42.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$216
  • Alcon$205
  • Rxsight Inc$173
  • Tarsus Pharmaceuticals, Inc.$125
  • Lombart Brothers, Inc.$45
  • Dompe US, Inc.$22
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$802100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson Vision Care, Inc.6$216
Alcon7$205
Rxsight Inc2$173
Tarsus Pharmaceuticals, Inc.1$125
Lombart Brothers, Inc.1$45
Dompe US, Inc.1$22
Thea Pharma Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$802 in reported general payments places this provider in the 65th percentile of 684 optometrist providers in Oregon.

See all optometrist providers in Oregon

Medicare billing

Part B allowed, 2024
$28,291
Medicare patients
209
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$9,580
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha14$162

Paid to pharmacies, not to this prescriber.

Other optometrist in Lake Oswego

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →